We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Chemotherapy resistant Burkitt lymphoma: Possible novel therapies including CAR‐T cell infusion.
- Authors
Geerts, Paulus A. F.; 't Hart, Nils; Visser, Otto; Ortiz‐Maldonado, Valentín; Chamuleau, Martine E. D.
- Abstract
Key Clinical Message: The prognosis of patients with relapsed or refractory (R/R) BL is poor with limited response to salvage therapy, especially for patients with early relapse (<6 months) or refractory disease. Novel therapies may be promising but need refinement. The prognosis of patients with relapsed or refractory (R/R) BL is poor with a limited response to salvage therapy, especially for patients with early relapse (<6 months) or refractory disease. We present three cases of patients with R/R BL receiving novel therapies followed by a literature review. Amongst others, the patients received inotuzumab ozogamicin, idelalisib, ibrutinib, and CAR‐T cell therapy, however, with limited response. In literature, response to several novel agents is described; however, most promising results are seen with CAR‐T cell therapy. Concluding from case series, sequential CAR‐T cell therapy, targeting multiple B‐cell antigens, seems most promising.
- Subjects
LITERATURE reviews; SALVAGE therapy; LYMPHOMAS; DISEASE relapse; CELLULAR therapy
- Publication
Clinical Case Reports, 2023, Vol 11, Issue 6, p1
- ISSN
2050-0904
- Publication type
Case Study
- DOI
10.1002/ccr3.7361